Related Experiment Video

Updated: Aug 13, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that

John T Mullen1, James M Donahue, Soundararajalu Chandrasekhar

  • 1Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.

Cancer
|August 12, 2004
PubMed
Abstract

Insights

This study introduces a novel oncolytic herpes simplex virus 1 (HSV-1) mutant, HSV-Endo, engineered to inhibit tumor growth by both direct viral destruction and anti-angiogenesis, leading to complete tumor regression in preclinical models.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Oncolytic herpes simplex virus 1 (HSV-1) demonstrates tumor cell destruction via viral replication.
  • Complete tumor regression is infrequently achieved with conventional oncolytic HSV-1 therapies.

Purpose of the Study:

  • To enhance the antitumor efficacy of oncolytic HSV-1 by incorporating the endostatin gene.
  • To develop a replication-conditional HSV-1 mutant (HSV-Endo) for dual-action cancer therapy.

Main Methods:

  • Constructed a replication-conditional HSV-1 mutant (HSV-Endo) encoding the murine endostatin gene.
  • Evaluated HSV-Endo's efficacy in vitro against colon carcinoma cell lines and in vivo in flank tumor models.
  • Assessed endostatin secretion, biological activity, and impact on viral replication.

Main Results:

  • HSV-Endo effectively destroyed colon carcinoma cells in vitro and induced tumor destruction in vivo.
  • Secreted endostatin from HSV-Endo-infected cells was biologically active and did not impede viral replication.
  • HSV-Endo treatment led to decreased tumor vascularization and complete tumor sloughing in some cases.

Conclusions:

  • The engineered oncolytic HSV-1 mutant, HSV-Endo, offers a dual therapeutic strategy.
  • HSV-Endo combines direct tumor cell lysis with the inhibition of tumor angiogenesis.
  • This dual mechanism promotes complete tumor regression, highlighting its potential in cancer treatment.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...